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Abstract
Hyperuricemia is linked to gout and features of metabolic syndrome. There is concern that dietary fructose may increase
uric acid concentrations. To assess the effects of fructose on serum uric acid concentrations in people with and without
diabetes, we conducted a systematic review and meta-analysis of controlled feeding trials. We searched MEDLINE,
EMBASE, and the Cochrane Library for relevant trials (through August 19, 2011). Analyses included all controlled feeding
trials $7 d investigating the effect of fructose feeding on uric acid under isocaloric conditions, where fructose was
isocalorically exchanged with other carbohydrate, or hypercaloric conditions, and where a control diet was supplemented
with excess energy from fructose. Data were aggregated by the generic inverse variance method using random effects
models and expressed as mean difference (MD) with 95% CI. Heterogeneity was assessed by the Q statistic and
quantiﬁed by I
2. A total of 21 trials in 425 participants met the eligibility criteria. Isocaloric exchange of fructose for other
carbohydrate did not affect serum uric acid in diabetic and nondiabetic participants [MD = 0.56 mmol/L (95% CI: 26.62,
7.74)], with no evidence of inter-study heterogeneity. Hypercaloric supplementation of control diets with fructose (+35%
excess energy) at extreme doses (213–219 g/d) signiﬁcantly increased serum uric acid compared with the control diets
alone in nondiabeticparticipants[MD = 31.0mmol/L(95% CI: 15.4, 46.5)]withno evidenceof heterogeneity. Confounding
from excess energy cannot be ruled out in the hypercaloric trials. These analyses do not support a uric acid-increasing
effect of isocaloric fructose intake in nondiabetic and diabetic participants. Hypercaloric fructose intake may, however,
increase uric acid concentrations. The effect of the interaction of energy and fructose remains unclear. Larger, well-
designed trials of fructose feeding at “real world” doses are needed. J. Nutr. 142: 916–923, 2012.
Introduction
Metabolic syndrome predisposes individuals to diabetes and
cardiovascular disease and affects over one-quarter of Ameri-
cans and Canadians, making it an important public health
concern (1,2). Metabolic syndrome is now deﬁned as the
presence of any 3 of the following 5 risk factors: elevated waist
circumference [central obesity], elevated TG ($1.7 mmol/L),
low HDL cholesterol (,1.0 mmol/L for men, ,1.3 mmol/L for
women) or drug treatment for low HDL cholesterol, elevated
blood pressure ($130/85 mm Hg) or antihypertensive drug
treatment, or elevated fasting glucose ($5.6 mmol/L) or drug
treatment for elevated blood glucose (3). Meanwhile, uric acid is
commonly associated with gout, an inﬂammatory condition
affecting 8.3 million Americans (4). Further, hyperuricemia has
been shown to be associated with components of metabolic
syndrome, including hypertension and diabetes (5–7). Hyperu-
ricemia is associated with obesity, excessive alcohol intake, and
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recently and the prevalence of hyperuricemia in U.S. adults is
estimated at 21.4% (4). Proposed mechanisms of uric acid-
mediated metabolic syndrome include the inhibition of endo-
thelial NO leading to hypertension; inﬂammation and oxidative
stress in adipocytes leading to insulin resistance; and increased
endothelial and smooth muscle oxidative stress (6,7).
Dietary factors are thought to be important modulators of
serum uric acid. Worldwide fructose intake, particularly in the
form of high fructose corn syrup, has paralleled the rise in
metabolic syndrome and hyperuricemia (8). High fructose con-
sumption is associated with features of metabolic syndrome
through an effect on uric acid (9,10). Fructose metabolism can
promote uric acid formation (7). Once absorbed into the cell,
unregulated phosphorylation of fructose by fructokinase leads
to local ATP depletion and increased AMP production, which
in turn increases uric acid (7). Early acute human studies
demonstrated elevated serum uric acid after fructose feeding
(11). Evidence from longer term fructose feeding trials (12–27)
and observational studies (10,28–32), however, have shown
mixed results.
There are currently no recommendations addressing the effect
of dietary fructose intake on uric acid and the risk of gout or
metabolic syndrome. Various health agencies, including the
American Diabetes Association, the European Association for
the Study of Diabetes, and the AHA, have discouraged high intakes
of fructose based on adverse affects on serum lipids (33–35). To
evaluate the need for additional clinical evidence regarding the
effects of fructose consumption on uric acid in humans, we
conducted a systematic review and meta-analysis of controlled
feeding trials to assess the effect of fructose on uric acid.
Methods
This systematic review and meta-analysis followed a similar methodo-
logical approach as Sievenpiper et al. (36). We followed the Cochrane
Handbook for Systematic Reviews of Interventions for the planning and
conduct of this meta-analysis (37). The reporting followed the Preferred
Reporting Items for Systematic reviews and Meta-Analyses guidelines
(38,39).
Study selection. We conducted a search of MEDLINE (1948 through
August 19, 2011), EMBASE (1974 through August 19, 2011), and the
Cochrane Central Register of Controlled Trials database (1950 through
August 19, 2011) using the search terms: fructose AND (uric acid OR
urate). Inclusion criteria is listed in Supplemental Table 1.
Data extraction. Three reviewers (D.W., V.H., L.C.) independently
extracted the following study characteristics: design (parallel or cross-
over), randomization, blinding, sample size, participant characteristics
(age, sex, BMI, and diabetes status), fructose form (solid, liquid, or
mixed), dose, control reference carbohydrates (sucrose, starch, glucose),
follow-up, and the macronutrient proﬁle of the background diet. The
quality of each study was assessed by each reviewer using the Heyland
methodological quality score (MQS)
13 (40), which assignsa score from 0
to 1 or 0 to 2 in 9 categories of quality related to study design, sampling
procedures, and interventions for a total of 13 points. Disagreements
were reconciled by consensus through discussion with another investi-
gator (J.L.S.). The fasting serum uric acid concentration (mean 6 SD)
was extracted as the main endpoint. All trials reported end differences.
We calculated missing SD values from available statistics using standard
formulae (37). Where these data were not reported preventing calcula-
tion, we imputedSD values using a pooled correlation coefﬁcient derived
from a meta-analysis of correlation coefﬁcients from those trials
reporting sufﬁcient data. We derived correlation coefﬁcients for individ-
ual trials according to a standard formula (37,41). We then input these
values into the meta-analysis as transformed Z-scores 6 SE, from which
we derived the pooled correlation coefﬁcient. If SD coefﬁcients still could
not be imputed, then we derived the missing SD from the pooled SD
imputed for the other trials (42).
Statistical analyses. Data were analyzed using Review Manager
(RevMan) version 5.0.25 (The Nordic Cochrane Centre, The Cochrane
Collaboration). Separate pooled analyses for isocaloric and hypercaloric
fructose feedingtrials were conducted usingthe Generic Inverse Variance
method using random effects models. Analyses were stratiﬁed by
diabetes and nondiabetes. The outcome studied was end differences in
serum uric acid. Potential sources of methodological heterogeneity were
investigated by sensitivity analyses and a priori subgroup analyses,
investigating the effect of comparator (starch, sucrose, glucose]) fructose
format (ﬂuid, mixed, solid), dose [Canadian Diabetes Association
thresholds: #60 or .60 g/d (43)], follow-up (#4 wk, .4 wk), study
quality [Heyland MQS ,8, $8 (40)], randomization, and study design
(parallel or crossover). Meta-regressions were performed to assess the
signiﬁcance of subgroup effects (STATA 11.2). Publication bias was
investigated byvisualinspectionof funnelplotsand formallytestedusing
Begg (44) and Egger (45) tests.
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Search results. The systematic search and selection of the
literature is outlined (Supplemental Fig. 1). A total of 375
reports were identiﬁed as eligible from the initial search, of
which 340 reports were excluded based on the title or abstract.
The remaining 35 reports were retrieved and reviewed, whereas
a further 19 were excluded. A total of 16 met the eligibility
criteria and were included in this meta-analysis. These 16
reports contained 18 isocaloric trials (12–21,23–27) and 3
hypercaloric trials (22,23) and one of the reports contained both
an isocaloric and hypercaloric trial (23).
Trial characteristics. Trial characteristics are shown in Table 1.
Nine of the isocaloric trials were in 119 prediabetic and diabetic
participants with 12 comparison arms and 9 of the isocaloric
trials were in 271 nondiabetic participants with 8 comparison
arms. The 3 hypercaloric trials were in 35 nondiabetic partic-
ipants with 3 comparison arms. The mean age of participants
was 42.6 y old (23–62 y old) in the isocaloric trials and 24.4 y
old (24–24.6 y old) in the hypercaloric trials. Mean baseline uric
acid was 317 mmol/L (232–398 mmol/L) in isocaloric trials and
312 mmol/L (300–322 mmol/L) in hypercaloric trials. Eight
(44%) isocaloric trials and all 3 hypercaloric trials were
randomized. Twelve (67%) isocaloric and all 3 hypercaloric
trials used crossover designs. Starch (11 trial arms), sucrose
(6 trial arms), or glucose (4 trial arms) were used as the
comparator-carbohydrate in the isocaloric trials, whereas weight-
maintaining control diets were used as the comparator in the
hypercaloric trials. Fructose was administered in liquid, solid, or
TABLE 1 Characteristics of included trials
Study Participants
1 Age
2
Baseline
plasma
uric acid
3 Design
4 Setting
Feeding
control
5 Randomization
Fructose
dose
6 Fructose form
7 Comparator
8
Diet energy
CHO:fat:
protein Follow-up MQS
9
ny mmol/L g/d (%E) wk
Isocaloric trials
No diabetes
Crapo (15) 11 N; 4M, 7F 39.5 6 11.4 339 6 98.6 C IP, USA Supp No ;81 (13.2) MX Sucrose 55:30:15 2 7
Forster (17) 6 N; 4M, 2F 23 (20–26) 309 6 77 C IP, GER Met No 162 (33) MX Glucose 92:00:08 2.9 7
Hallfrisch (19) 12 N; 12M, 0F 39.8 6 8.3 324 6 82.3 P IP/OP, USA Met No ;101 (15) SO Starch 43:42:15 5 7
12 HI; 12M, 0F 39.5 6 7.3 371 6 82 P IP/OP, USA Met No ;101 (15) SO Starch 43:42:15 5 7
Huttunen (20) 68 N; 35 fructose,
33 sucrose
27.5 6 7.0 320 6 57.4 P OP, FIN Supp No 69.1 MX Sucrose — 95 5
Koh (21) 9 N; 3M, 6F 50 6 15 333 6 53.5 C IP/OP, USA PM No ;78.5 (15) MX Glucose 52:32:16 4 8
Madero (27) 109 N; 7M, 102F 38.8 6 8.8 329 6 8.3 P OP, MEX Supp Yes ;60 (13) MX Starch 55:30:15 6 6
Ngo Sock (23) 11 N; 11M, 0F 24.6 6 2.0 330 6 29.8 C OP, SUI Met Yes ;213 (26) LQ Glucose 55:30:15 1 8
Reiser (26) 11 N; 11M, 0F; 10 HI;
10M, 0F
43.5 (23–64) 312 6 82.3 C OP, USA Met No 167 (20) MX Starch 51:36:13 5 4
Diabetes/prediabetes
Anderson (12) 14 DM2; 14M, 0F 60 6 4 360 6 82.3 C OP, USA PM No ;55 (12) MX Starch 55:25:20 23 8
Bantle (13) 12 DM1; 6M, 6F;
12 DM2; 5M, 7F
62 (36–80) 244 6 82.3 C IP/OP, USA Met Yes ;136.5 (21) MX Starch 55:30:15 1.1 8
12 DM1; 6M, 6F;
12 DM2; 5M, 7F
62 (40–72) 250 6 82.3 C IP/OP, USA Met Yes ;136.5 (21) MX Sucrose 55:30:15 1.1 8
Blayo (14) 11 DM1; 3 DM2 46.9 6 13.1 232 6 82.3 P OP, FRA Supp Yes ;25 (5) MX Starch 55:30:15 52 7
8 DM1; 4 DM2 46.9 6 13.1 244 6 82.3 P OP, FRA Supp Yes ;25 (5) MX Sucrose 55:30:15 52 7
Crapo (16) 7 DM2; 3M, 4F 50.9 6 8.4 357 6 158 C IP, USA Met No ;97.5 (13.2) MX Sucrose 55:30:15 2 7
Grigo resco (18) 8 DM2; 5M, 3F 40 6 6.9 354 6 102 C OP, FRA Supp Yes 30 (8) LQ Starch 50:30:20 8 8
Koh (21) 9 prediabetes; 3M, 6F 50 6 15 398 6 35.7 C OP, FRA PM No ;78.5 (15) MX Glucose 52:32:16 4 8
Osei (24) 13 DM2; 5M, 8F 54 6 10.8 274 6 111 C OP, FRA Met Yes 60 (7.5) MX Starch 55:35:15 26 8
Osei (25) 18 DM2; 3M, 15F 57 6 3.0 340 6 144 P O, USA Supp Yes 60 (10) MX Starch 55:35:15 12 8
Hypercaloric trials
No diabetes
Le (22) 8 N; 8M, 0F 24.7 6 5.2 300 6 22.6 C OP, SUI Met Yes ;213 (+35) LQ Diet alone 55:30:15 1 8
16 OffDM; 16M, 0F 24 6 2.7 322 6 20.0 C OP, SUI Met Yes ;219 (+35) LQ Diet alone 55:30:15 1 8
Ngo Sock (23) 11 N; 11M, 0F 24.6 6 2.0 313 6 29.8 C OP, SUI Met Yes ;213 (+35) LQ Diet alone 55:30:15 1 8
1 C, crossover; CHO, carbohydrate; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; E, energy; F, female; Fin, Finland; Fra, France; Ger, Germany; HI, hyperinsulinemic; IP,
inpatient; LQ, liquid; M, male; Met, metabolic; Mex, Mexico; MQS, methodological quality score, MX, mixed; N, normal; OffDM, offspring of type 2 diabetes mellitus; OP, outpatient; P, parallel;
PM, partial metabolic; SUI, Switzerland; Supp, supplement; SO, solid; USA, United States.
2 Values are mean 6 SD or mean (range).
3 Baseline or control treatment (comparator) concentrations are mean 6 SD.
4 Designs were either C or P.
5 Met feeding control represents the provision of all meals, snacks, and study supplements (test sugars and foods) consumed during the study under controlled conditions. PM feeding control
represents the provision of some meals and snacks and all study supplements (test sugars and foods) consumed during the study under controlled conditions. Supp feeding control represents
the provision of study supplements.
6 Doses were administered on a g/d, percentage energy, or g/kg body weight basis. Doses preceded by approximate symbol represent average doses calculated based on the average reported
energy intake or weight of participants. If these data were not available, then the average dose was based on a 2000-kcal intake preceded by approximate symbol represent average doses.
7 Fructose was provided in 1 of 3 forms: LQ form, where all or most of the fructose was provided as beverages or crystalline fructose to be added to beverages; SO form, where fructose was
provided as solid foods (fruit in the one case); or MX form, where all or most of the fructose was provided as a mix of beverages, solid foods (not fruit), and/or crystalline fructose.
8 Comparator refers to the reference carbohydrate (starch, sucrose, or glucose) in the isocaloric trials and diet alone (weight maintaining, background diet) in the hypercaloric trials. Fructose was
exchanged for the reference carbohydrate providing an energy matched comparison in the isocaloric trials, whereas it was added to the diet alone providing excess energy relative to the
diet alone in the hypercaloric trials.
9 Study quality was assessed by the Heyland MQS. Trials scored $8 were considered to be of higher quality.
918 Wang et al.mixed formats at a mean dose of 94 g/d [25–213 g/d or 5–33%
energy (E)] in the isocaloric trials and 215 g/d (213–219 g/d or +35%
excess E) in the hypercaloric trials. Thirteen (72%) of the isocaloric
trials and all 3 of the hypercaloric trials exceeded the dose threshold
of 60 g/d proposed by the Canadian Diabetes Association (13,15–
17,19,20,22,23,26). Nine (50%) isocaloric and all 3 hypercaloric
trials used metabolically controlled designs. Background diets in the
isocaloric and hypercaloric trials provided a wide range of macro-
nutrient proﬁles. Isocaloric trial diets consisted of 43–92% E
carbohydrate, 0–42% E fat, and 8–20% E protein. All hypercaloric
trial diets consisted of 55% E carbohydrate, 30% E fat, and 15% E
protein. The mean follow-up was 14.4 wk (1–95 wk) in the
isocaloric trials, whereas all 3 hypercaloric trials lasted 1 wk. The
Heyland MQS in the isocaloric trials ranged from 4 to 8 with 9 trials
(50%)considered tobeofhigherquality (MQS$8). All hypercaloric
trials were of higher quality with an MQS score of 8.
Isocaloric feeding trials. The effect of fructose in isocaloric
exchange for other carbohydrate on uric acid was not signiﬁcant
in prediabetic/diabetic participants mean difference (MD) =
24.09 (95% CI: 223.7, 15.6)] and nondiabetic participants
[MD = 1.28 (95% CI: 26.65, 9.22)] (Fig. 1). The lack of effect
was found consistently across trials without any evidence of
inter-study heterogeneity (I
2 = 0% in both groups). Systematic
removal of trials during sensitivity analyses did not alter the
conclusions. There was no signiﬁcant effect in any of the a prioi
subgroups and no signiﬁcant evidence of heterogeneity (Fig. 2).
Hypercaloric feeding trials. There was a signiﬁcant effect of
hypercaloric (+35% E) fructose on serum uric acid in partici-
pants without diabetes (Fig. 3). A large uric acid-raising effect
[MD = 31.0 (95% CI: 15.4, 46.5); P , 0.05] of hypercaloric
(+35% E) fructose was seen without any evidence of inter-study
heterogeneity (I
2 = 0%; P = 0.97). A priori subgroup analyses
were not conducted owing to an insufﬁcient number of trials.
Publication bias. Funnel plots were inspected for the presence of
publication bias (Fig. 4). There was a suggestion of funnel plot
asymmetry with a lack of small trials favoring a uric-acid raising
effect of fructose; however, neither Egger nor Begg tests provided
sufﬁcient evidence of publication bias for uric acid (Egger test, P =
0.95; Begg test, P = 0.14).
Discussion
The present pooled analyses of 21 controlled feeding trials in
425 prediabetic/diabetic and nondiabetic participants demon-
strate that the uric acid response to fructose feeding differs
FIGURE 1 Forest plots of feeding trials investigating the effect of isocaloric exchange of fructose for carbohydrate on uric acid in people with
and without diabetes. Three pooled effect estimates (diamonds) are shown: one each for trials in individuals with diabetes, no diabetes, and their
combination. Paired analyses were applied to all crossover trials. Data are for weighted MD with 95% CI in uric acid (mmol/L). Data are expressed
as weighted MD with 95% CI using generic inverse variance random effects models. Inter-study heterogeneity was tested by Cochrane’s Q
statistic (chi-square) at a significance level of P , 0.10 and quantified by I
2, where I
2 $ 50% is considered to be evidence of substantial
heterogeneity and $75%, considerable heterogeneity. CHO, any carbohydrate comparator; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes
mellitus; IGT, impaired glucose tolerance; HI, hyperinsulemia; MD, mean difference; N, normal.
Fructose and uric acid 919between isocaloric and hypercaloric feeding conditions. Isoca-
loric fructose intake did not raise uric acid, whereas hypercaloric
fructose intake did. The mean increase in the hypercaloric trials
was 31.0 mmol/L.
The clinical and practical importance of the increase in uric
acid in the hypercaloric trials is unclear. The 3 hypercaloric trials
in this meta-analysis fed fructose at 35% excess E (852–876
kcal/d or 213–219 g/d) in ﬂuid form in nondiabetic males for
1 wk, a level of exposure that is more than double the 95th
percentile (87 g/d) of fructose intake in the US (46). At these
tremendous doses, the resulting 31.0-mmol/L increase in uric
acid has the potential to place many individuals at risk of
hyperuricemia (.416 mmol/L in men or .339 mmol/L in
women), where the mean serum urate concentrations in U.S.
adults are 365 mmol/L in men and 290 mmol/L in women (4).
Extreme fructose doses inducing hyperuricemia have also been
studied in the past. Perez-Pozo et al. (10) conducted a random-
ized, 2-wk crossover trial in which participants were random-
ized to either allopurinol, a xanthine oxidase inhibitor which
inhibits the production of uric acid, or placebo while consuming
200 g/d of fructose for 2 wk. Allopurinol was shown to decrease
the fructose-induced rise in uric acid by 65 mmol/L. Although
this increase was reported under weight-maintaining conditions,
the evidence from observational studies suggests that an excess
of energy may be a prerequisite for a sustainable uric acid-
increasing effect of fructose. In models not adjusted for total
energy or carbohydrate intake, high fructose intake increased
uric acid in the NHANES III (32); however, in energy- and
nonfructose carbohydrate-adjusted models, no effect of total
fructose was found on either uric acid concentrations or risk of
gout in NHANES 1999–2004 (32). Although these data taken
together with our ﬁndings highlight possible confounding from
excess energy at high doses, the small number of trials in our
hypercaloric analysis limits the conﬁdence in our estimates.
In the isocaloric setting, there was no effect of fructose
substitution for other carbohydrate on uric acid concentrations.
This lackof effect contradicts datafrom the HealthProfessionals
Follow-up study that found that sweetened soft drink intake
(equivalent to ; $100 g/d of fructose as high fructose corn
syrup) was associated with a 29.1-mmol/L increase in uric acid
FIGURE 2 Subgroup analyses in the isocaloric
feeding trials investigating the effect of isocaloric
exchange of fructose for carbohydrate on uric acid
in people with and without diabetes. Points for each
subgroup level are the pooled effect estimates
expressed as weighted MD with 95%CI using
generic inverse variance random effect models.
The dashed line represents the pooled effect
estimate for the total analysis. CHO, any carbohy-
drate comparator; MD, mean difference.
FIGURE 3 Forest plots of feeding trials investigating the effect of hypercaloric fructose feeding on serum uric acid under hypercaloric
conditions, where a control diet was supplemented with excess energy from fructose, in people without diabetes. Data are for weighted MD
with 95% CI in uric acid (mmol/L). Data are expressed as weighted MD with 95% CI using generic inverse variance random effects models. Inter-
study heterogeneity was tested by Cochrane’s Q statistic (chi-square) at a significance level of P , 0.10 and quantified by I
2, where I
2 $ 50% is
considered to be evidence of substantial heterogeneity and $75%, considerable heterogeneity. CHO, any carbohydrate comparator; MD, mean
difference; N, normal healthy participants; ODM2, offspring of type 2 diabetes mellitus.
920 Wang et al.concentrations (29). Similarly, an analysis of NHANES III found
that isocaloric substitution of sugar-sweetened beverages (equiv-
alent to ;$16% E as fructose) for other energy was associated
with a 25.0-mmol/L increase in uric acid and a multivariate OR
of 1.82 for hyperuricemia (29). The reason for the discordance
between these observational data and our meta-analysis of
controlled feeding trials is unclear. It is possible that there may
be a threshold for fructose-mediated ATP depletion/AMP
production, which is thought to lead to increased uric acid
concentrations. The mean fructose dose in the isocaloric trials
(93.4 g/d)was below the level of exposure associated with higher
uric acid concentrations in the observational studies, which may
also have incompletely adjusted for energy compensation. It was
also well below the mean dose used in our included hypercaloric
trials (215 g/d) used to induce higher uric acid concentrations
and the animal models (60% E as fructose, which is equivalent
to 300 g/d on a 2000-kcal diet) used to elucidate the mechanism
of fructose-induced uric acid production (9). A fructose dose
threshold has been observed in clinical trials, below which the
effects on other metabolic biomarkers are lost, e.g., #60 g/d in
type 2 diabetes (36) and ,100 g/d across all subject types (47)
for TG. Additionally, there is evidence of fructose intolerance
and incomplete absorption at higher doses and concentrations,
further confounding results from trials at high doses (48).
Population-level intakes of fructose, where the 50th percentile of
fructose intake in the US is 49 g/d (46), may be unlikely to elicit
this mechanism in a clinically signiﬁcant way. Both dose alone and
dose in relation to excess energy, therefore, are important consid-
erations in assessing adverse effects of fructose on uric acid.
The strengthof the present analyses is the lack of both statistical
heterogeneity and clinical heterogeneity. Neither stratiﬁcation of
the data nor a priori subgroup analyses altered the signiﬁcance of
the effect estimates or heterogeneity. The lack of an effect of
fructose in isocaloric exchange for carbohydrate on uric acid was
robust to stratiﬁcation by diabetes status. It was also not modiﬁed
by dose at a lower threshold (# or .60 g/d), comparator (starch,
sucrose, and glucose), follow-up (, or $4w k ) ,d e s i g n( c r o s s o v e r ,
parallel), study quality (MQS $ or ,8), randomization (yes, no),
or fructose form (solid, liquid, mixed). Although not tested
formallyin subgroup analyses, compositionof the background diet
in the trials also did not appear to have an effect. One of the
included isocaloric trials, Forster et al. (17), had a background diet
devoid of fat. This study was included, because it met all eligibility
criteria. Removal of this trial during sensitivity analyses did not
alter the conclusions, although this trial should be interpreted
cautiously. The consistency across these different trial conditions
helps to strengthen the generalizability of our conclusions.
Our analyses, nevertheless, have several limitations. First,our
literature search would not have identiﬁed trials that measured
uric acid and displayed uric acid data but was only discussed
withina tableor ﬁgure.Second,the hypercaloric studies recruited
only men; previous studies have shown both sex and hormone
effects on uric acid concentrations. Men generally have higher
concentrations of uric acid than women and hormones play a
role. Estrogen can reduce uric acid concentrations, mitigating
many of the metabolic effects of uric acid (49), whereas testos-
terone has been associated with increased uric acid (50). Although
the data support increased uric acid concentrations in men, we
could not determine from the existing data the effects of
hypercaloric fructose on women. Third, only 5 of the included
isocaloric trials and none of the hypercaloric trials were longer
than12wk.Althoughwefoundno evidenceofeffectaccordingto
follow-up, it is unclear whether the lack of effect of isocaloric
fructose exchange for other carbohydrates on uric acid would be
sustainable over the long term. It is also unclear whether
isocaloric exchange conditions can be maintained over the long
term. Longer-term trials would be helpful in separating out the
short-term from the longer-term effects of fructose. Fourth, study
quality was poor (MQS ,8) in 50% of the included trials.
Complicating this issue was the incomplete reporting in many
publications requiring a fair degree of imputations (7/18 trials
requiredimputations).Therewas, however,noeffect (P = 0.97)of
MQS (,8v s .$8) in subgroup analyses. Although the use of a
quality scoring method, such as the MQS, may have been
inadequate (51), the consistent lack of effect of all a priori
subgroups (Fig. 2) supports the lack of a uric acid–raising effect
(P . 0.2 for all comparisons) of isocaloric fructose exchange for
other carbohydrates. Fifth, only two-thirds of the isocaloric trials
used crossover designs. However, Lathyris et al. (52) performed a
systematic review of Cochrane Reviews and found generally
good agreement between parallel and crossover trials. Finally,
publication bias was a possibility in both the isocaloric and
hypercaloric trials. Visual inspection of funnel plots for both sets
of trials along with Egger or Begg tests found limited evidence of
funnel plot asymmetry and publication bias.
In conclusion, our work suggests that contrary to concerns,
isocaloric fructose exchange for other sources of carbohydrate
does not raise uric acid concentrations and this lack of effect
holds across different experimental conditions. These conclu-
sions, however, arelimited bythe short follow-up of the majority
of trials and poor quality of one-half of the trials included in the
meta-analysis. On the other hand, high fructose intake (213–219
g/d) under hypercaloric feeding conditions (+35% E) does raise
serum uric acid concentrations, although confounding from
excess energy cannot be ruled out in these trials. These data
highlight the need for larger and longer fructose feeding trials
conducted under free-living conditions to assess whether fruc-
tose consumption leads to excess energy intake and whether in
turn the effects on uric acid are dependent on excess energy.
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FIGURE 4 Funnel plots for the effect of fructose in isocaloric
exchange for other carbohydrate on uric acid. The dashed lines
represent the pooled effect estimate expressed as a MD. The solid
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